Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.

NCT00775138 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Bronchiectasis

Interventions

DRUG: 280 mg Arikayce™
DRUG: Matching Placebo for Cohort 1
DRUG: 560 mg Arikayce™
DRUG: Matching Placebo for Cohort 2

Sponsor

Insmed Incorporated